-
ABOUT USAffiliated to SSY Group Limited, Hebei Guangxiang Technology Co., Ltd., is a high-tech enterprise specializing in drug research and technology development.
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the synergy between “industry, academia, research and application” based on multi-disciplinary integration and multi-directional combination.
-
SUBORDINATEThe group has decided to establish research institutes in its subsidiaries, Hebei Ghuangxiang Drug Research Institute, Jiangsu Best Medical Material Research Institute, and Hebei Hanlin Biological Research Institute.
-
RECRUITWe actively establish a joint talent cultivation mechanism between schools and enterprises, and currently have over 500 high-level talents in various fields such as drug research, analysis, and clinical practice.
-
CONTACTWe will continue to strengthen innovation-driven development, vigorously promote the integration of production and research, constantly improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs.
Shijiazhuang No.4 Pharmaceutical Co., Ltd. signed a strategic cooperation framework agreement with the North China Branch of Sinopec Chemical Sales Co., Ltd.
Category:
Time：2021-06-08
On June 8, the signing ceremony for the deepened cooperation framework agreement between Shijiazhuang Sihua Pharmaceutical Group and the North China Branch of Sinopec Chemical Sales Co., Ltd., as well as the unveiling ceremony for the “Innovative Application Demonstration Base for Synthetic Resin Medical and Healthcare Materials,” were held at Shijiazhuang Sihua Pharmaceutical Group. The two parties will engage in in-depth cooperation in areas such as scientific and technological research and development and industrialization of medical packaging materials and related projects, thereby achieving mutual benefit and win-win outcomes.
Wu Hengyao, President of Shijiazhuang Sihua Pharmaceutical Group, and Rong Gang, Deputy General Manager of Huabei Chemical Sales, signed a cooperation agreement.
According to the agreement, both parties will commit to leveraging their respective strengths and promoting win-win cooperation. Sinopec Chemical Sales Co., Ltd. North China Branch will fully capitalize on its advantages in synthetic materials product development and industrial-scale transformation, while Shijiazhuang Fourth Pharmaceutical Group will draw on its strengths in pharmaceutical product design, R&D, production, sales, service, and technological development. Together, they will establish a collaborative model integrating production, sales, research, and application. Both sides will also shoulder their social responsibilities within the industry, focusing on the cutting edge of science and technology in the pharmaceutical sector and engaging in comprehensive cooperation on advanced, green, and environmentally friendly new materials. In doing so, they will make greater contributions to the advancement and development of China’s pharmaceutical industry and the deep processing of the chemical industry.
Yanshan Petrochemical, a subsidiary of Sinopec, the North China Branch of Sinopec Chemical Sales Co., Ltd., and Shijiazhuang Fourth Pharmaceutical Group have forged a deep friendship through their long-term business cooperation. They have also explored and established a new, mutually beneficial business model featuring collaboration between suppliers and technology partners, further strengthening the foundation of their strategic partnership.
Speech by Su Xuejun, Chairman of Shijiazhuang Fourth Pharmaceutical Group
Speech by Ma Ming, Deputy Director of the Beijing Research Institute of Chemical Industry
Wang Qiang, representative of the North China Sales Branch and Party Secretary, delivered a speech.
Su Xuejun, Chairman of Shijiazhuang Fourth Pharmaceutical Group, stated that the signing of the “Framework Agreement on Deepening Cooperation” has opened a brand-new chapter for mutually beneficial cooperation and joint development between the two sides. This move is a practical step taken by both parties to implement the new development philosophy and accelerate the realization of the “dual-circulation” development strategy. It holds extremely significant importance for ensuring the safety of medicines used by the people and promoting the localization of pharmaceutical packaging materials. Wang Qiang, Secretary of the Party Committee of the North China Branch of Sinopec Chemical Sales Co., Ltd., said that they will further strengthen the cooperation model between the two sides, broaden cooperation channels, establish and improve cooperation coordination mechanisms, fully implement the strategic agreement, and achieve mutually beneficial and win-win development.
The leaders of both sides jointly unveiled the “Demonstration Base for Innovative Applications of Synthetic Resin Medical and Healthcare Materials.”
According to the introduction, the North China Branch of Sinopec Chemical Sales Co., Ltd. is affiliated with Sinopec Chemical Sales Co., Ltd. and is responsible for the coordinated management of chemical product resources, marketing, product sales, logistics operations, and customer service in the North China, Northeast, and Northwest regions. It also handles the procurement and supply of chemical raw materials for chemical product manufacturers within these regions. The North China Branch is committed to practical and effective work, seizing the significant historical opportunities presented by the Belt and Road Initiative, the coordinated development of the Beijing-Tianjin-Hebei region, and the construction of the Xiong'an New Area. With a multi-point strategic layout, the branch is diligently building itself into a showcase for Sinopec’s green, low-carbon, and energy-efficient new materials. Yanshan Petrochemical, established in 1969, has fully leveraged the unique advantages of state-owned enterprises since its founding, becoming a strong defender of national economic security, energy security, and material security.
The ceremony was chaired by Wang Chunfa, CEO of Shijiazhuang Fourth Pharmaceutical Group.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Mobile site
E code